Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

LithuaniaBack to Lithuania

Clinical trials in Vilnius – page 2

189 clinical trials in Vilnius, Lithuania across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

LithuaniaOur site in LithuaniaKlinikiniai-Tyrimai.lt(opens in a new tab)
Vilnius at a glance
189
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

189 trials in Vilnius

Open in trial search

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Chronic graft versus host disease

Recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hereditary haemorrhagic telangiectasia

Recruiting

A Phase 3 Study of Engasertib to Evaluate Safety and Effectiveness in Adults with Moderate to Severe Hereditary Hemorrhagic Telangiectasia

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Sponsor:Vaderis Therapeutics AG

Neovascular age-related macular degeneration

Recruiting

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

Systemic scleroderma

Recruiting

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Coagulation factor X level

Recruiting

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Acute myeloid leukaemia

Recruiting

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:LithuaniaLithuania
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Acute myeloid leukaemia

Recruiting

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug
Countries:LithuaniaLithuania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.

Other cities in Lithuania

The busiest research cities in the country

All 10 cities in Lithuania

Clinical research in Vilnius

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on lung cancer treatments and respiratory conditions, including multiple trials for advanced NSCLC and studies examining new therapies for asthma management.

  • Non-small cell lung cancer treatments
  • Asthma control therapies
  • Small cell lung cancer interventions

Studies combine immunotherapy approaches with traditional treatments to improve patient outcomes.

02 Autoimmune Conditions

Comprehensive research into various autoimmune disorders, including Sjögren's syndrome, systemic lupus erythematosus, and inflammatory conditions.

  • Crohn's disease treatments
  • Rheumatoid arthritis therapies
  • Novel biological treatments

Trials focus on developing targeted therapies to manage chronic autoimmune conditions.

03 Hematology & Oncology

Advanced research in blood disorders and cancers, including studies on acute myeloid leukemia and myelodysplastic syndromes.

  • Leukemia treatments
  • Anemia therapies
  • Blood cancer interventions

Investigations include both pediatric and adult populations with various blood disorders.

Back to LithuaniaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.